Loading stock data…
GRFS
$7.80-0.30 (-3.70%)
Market ClosedLast close May 11
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Grifols, S.A. in the Healthcare sector is trading at $7.80. The stock is currently near its 52-week low of $7.36, remaining 14.6% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why GRFS maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.80
Potential Upside
67.8%
Whystock Fair Value$13.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Buy
Mean target$10.87+39.3%
Range$10.00 – $11.73
Fundamentals
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.44B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.41
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.21
Div Yield
Strong income play. Yield provides a meaningful total return floor.
2.18%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.75%
Volume
Today's trading volume
804,454
Recent News
European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading
European equities traded in the US as American depositary receipts opened the week on a flat note Mo
Grifols (BME:GRF) Valuation Check After Mixed Short And Long Term Share Price Performance
Why Grifols Stock Is on Investors’ Radar Grifols (BME:GRF) has drawn fresh attention after a period where returns have diverged across timeframes, with gains over the past year contrasting with weaker moves in the month and past 3 months. At a last close of €8.94, the stock reflects recent short term pressure. At the same time, longer term figures and the current earnings profile, including €7,438.0m in revenue and €415.0m in net income, keep the company in focus for investors assessing risk...
Grifols Q1 Earnings Call Highlights
Grifols (NASDAQ:GRFS) executives said the company began 2026 in line with its internal plans, pointing to continued strength in immunoglobulins, early progress in expanding plasma sourcing outside the U.S., and further steps to improve its debt profile and liquidity. On the company’s first-quarter
Grifols shares slide 4% as margin miss soured Q1 profit jump
Investing.com -- Shares in Grifols SA fell over 4% on Friday after the Spanish plasma therapeutics company reported first-quarter 2026 gross margin of 36.5%, against a consensus estimate of 40.5%.
European Equities Traded in the US as American Depositary Receipts Start Week Lower
European equities traded in the US as American depositary receipts kicked off the week lower late Mo